Opening soon. Stay in the loop

goodmorrowJoin the opening list

AOD-9604, explained.

Growth hormone fragment 176-191. Research, safety questions, and treatment context.

Updated Clinical review pending · Educational draft

The form

More than one catalog form

The routine

There is no established effective weight-management schedule for these catalog forms.

The evidence

Weight-loss benefit not demonstrated in a large trial

Forms listed in a June 2025 catalog. Current availability and individual instructions need confirmation.

Legal status
No lawful route today

No lawful compounding route today.

At Goodmorrow
We offer an alternative

What it is

AOD-9604 is a modified piece from the end of the human growth hormone molecule, designed to keep growth hormone's effect on fat without its other effects.

What the evidence shows

Early trials looked promising. A larger trial in the 2000s didn't show enough weight loss compared with placebo, and development for obesity stopped.

How Goodmorrow handles it

For fat loss, we prescribe GLP-1 medication. In their main trials, average weight loss ranged from about 11 to 21 percent depending on the drug.

Questions people ask

Is AOD-9604 better than semaglutide?

No. Semaglutide has large trials showing around 15 percent average weight loss. AOD-9604 didn't beat placebo convincingly.

Sources

  1. Secondary sourceAOD-9604: Research, Status and Evidence Superpower
  2. Secondary sourceThe Peptide Reclassification Everyone's Talking About: A Pharmacist's Take Pharmacy Times, 2026
  3. Research publicationOnce-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) New England Journal of Medicine, 2021

Good days ahead.

Join the opening list for appointment updates.

Join the opening list